Indeed, ASPP2 expression is frequently suppressed in a variety of human cancers, such as breast cancer[14] and lymphoma subtypes, where low ASPP2 mRNA expression levels are associated with biologically more aggressive lymphoma subtypes and with poor clinical outcome[17]. This evidence concerns the gene TP53BP2 and breast cancer.